ANTHEM Q2 FY27 Concall Summary & Key Takeaways (ANTHEM)

ANTHEM Q2 FY27 (Sep-2026 Qtr) Earnings call highlights: Key takeaways, performance, financial metrics, outlook and guidance, concerns and management tone.

  • ANTHEM Financials
  • ANTHEM Shareholding Pattern
  • ANTHEM Earnings Documents
  • ANTHEM Announcements
  • ANTHEM Corporate Actions
  • ANTHEM Bulk, Block & Insider Deals
  • ANTHEM Delivery Data
  • ANTHEM Earnings Concalls
  • Market Timeline
  • Concall Monitor
  • Company Research
  • Earnings Monitor
  • Upcoming Results
  • Sector Monitor
  • Sector Performance
  • Bulk & Block Deals
  • Delivery Data
  • FII & DII Activity
  • Market Indices
  • Plans & Pricing

Anthem Biosciences Ltd (ANTHEM) Q2FY27 Concall Summary - Sep-2026 Qtr

Key Takeaways

  • Management maintains its two-year CapEx guidance of INR 1,200 crores for the new Unit 4, with 30-35% allocated to expanding biologics and fermentation capabilities.
  • One late-stage molecule was commercialized in Q2, part of a recent cohort of five new products with an estimated combined market potential exceeding $10 billion.
  • The company is confident of sustaining its full-year FY26 EBITDA margin level (around 43%) for FY27, despite the exceptionally high 50.6% margin reported this quarter.

Performance Overview

  • Anthem Biosciences Ltd. reported a robust performance for Q2 FY27, driven by strong growth in the CRDMO business.
  • The company successfully transitioned one late-stage molecule to the commercial stage, increasing its commercial portfolio to 15 molecules.
  • Strict discipline around cost efficiencies and yield optimization resulted in expanded EBITDA and PAT margins year-on-year.
  • The company maintained a strong net cash position of INR 1,534 crores as of September 30, 2026.
  • Underlying demand for the company's services remains strong, with an increase in RFPs and RFQs noted in the last quarter.

Financial Metrics

Log in to Stocksigma to read the Financial Metrics section of this summary.

Operating Performance / Business Segments

Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.

Key Discussions & Insights

Log in to Stocksigma to read the Key Discussions & Insights section of this summary.

Outlook and Guidance

Log in to Stocksigma to read the Outlook and Guidance section of this summary.

Challenges / Concerns

Log in to Stocksigma to read the Challenges / Concerns section of this summary.

Industry / Competitive Landscape

Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.

Overall Summary

Log in to Stocksigma to read the Overall Summary section of this summary.

Tone & Disclosure

Log in to Stocksigma to read the Tone & Disclosure section of this summary.

  • ANTHEM Q2FY27 Concall Transcript
  • ANTHEM Q2FY27 Management Mirror
  • ANTHEM Q1FY27 Concall Summary (Jun-2026 Qtr)